Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
IL-17
Pharma
J&J's Tremfya may be answer for PsA patients with axial disorder
Analysis of two phase 3 trials of Tremfya in psoriatic arthritis patients shows the drug may also be effective against an inflammation disorder.
Kevin Dunleavy
Jun 29, 2021 6:30pm
Sanofi bags oral rival to Novartis' injectable Cosentyx
Apr 18, 2021 9:15am
Novartis' Cosentyx fizzles in head-to-head fight with Humira
Nov 1, 2019 10:48am
Lilly's Taltz tops Tremfya with 41% skin clearance in study
Oct 3, 2019 11:56am
Roche stakes claim on Eli Lilly’s psoriasis med Taltz
Jul 5, 2018 9:15am
Valeant undercuts psoriasis rivals with $3,500 Siliq price
Apr 21, 2017 9:37am
